English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aims  Haemodynamic‐guided heart failure ( HF ) management effectively reduces decompensation events and need for hospitalizations. The economic benefit of clinical improvement requires further study.    Methods and results  An estimate of the cost‐effectiveness of haemodynamic‐guided  HF  management was made based on observations published in the randomized, prospective single‐blinded  CHAMPION  trial. A comprehensive analysis was performed including healthcare utilization event rates, survival, and quality of life demonstrated in the randomized portion of the trial (18 months). Markov modelling with Monte Carlo simulation was used to approximate comprehensive costs and quality‐adjusted life years ( QALYs ) from a payer perspective. Unit costs were estimated using the Truven Health  MarketScan  database from April 2008 to March 2013. Over a 5‐year horizon, patients in the Treatment group had average  QALYs  of 2.56 with a total cost of  US $56 974; patients in the Control group had  QALYs  of 2.16 with a total cost of  US $52 149. The incremental cost‐effectiveness ratio ( ICER ) was  US $12 262 per  QALY . Using comprehensive cost modelling, including all anticipated costs of  HF  and non‐ HF  hospitalizations, physician visits, prescription drugs, long‐term care, and outpatient hospital visits over 5 years, the Treatment group had a total cost of  US $212 004 and the Control group had a total cost of  US $200 360. The  ICER  was  US $29 593 per  QALY .    Conclusions  Standard economic modelling suggests that pulmonary artery pressure‐guided management of  HF  using the  CardioMEMS ™  HF  System is cost‐effective from the  US ‐payer perspective. This analysis provides the background for further modelling in specific country healthcare systems and cost structures.

Pulmonary artery pressure‐guided heart failure management: US cost‐effectiveness analyses using the results of the CHAMPION clinical trial